
 is optionally substituted phenyl;



A is

B and E are a chemical bond;

a is 0-6;

b is 0-4;

c is 0;


d is 0;

g is 1-5;


R₁, R₂, R₃ and R₄ are, independently, hydrogen, halogen or optionally substituted alkyl;

Z is R₂₁O₂C-, R₂₁OC-, -CN, R₂₁O₂SHNCO-, R₂₁O₂SHN-, (R₂₁)₂NCO- or R₂₁O-; and R₂₁ is independently hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, or optionally substituted aralkyl;

R₁₅, R₁₆ are independently hydrogen, optionally substituted alkyl, optionally substituted aralkyl, carbonyl, or optionally substituted alkoxycarbonyl; or a pharmaceutically acceptable salt thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

2. (Twice Amended) A compound according to claim 1 wherein  is optionally substituted azaheteroaryl.

30. (Three Times Amended) A compound according to claim 1 wherein

 is an optionally substituted quinoliny, quinoxaliny, quinazoliny, isoquinoliny, N-alkyl-quinolin-4-onyl, quinazolin-4-onyl, benzoxazolyl,

benzimidazolyl, benzothiazolyl, benzofuranyl, benzothiophenyl, oxazolyl, thiazolyl, oxadiazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiadiazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl group, wherein the substituent is a ring system substituent.

D4 ¹⁵ 55. (Three Times Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound wherein the disorder is associated with a physiological detrimental blood level of insulin, glucose, free fatty acids, or triglycerides.

D5 ¹⁶ 56. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is hyperglycemia.

D6 ¹⁹ 59. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is hyperinsulinism.

D7 ²⁰ 61. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is insulin resistance.

21

07 62. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is a cardiovascular condition.

23

64. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is hyperlipidemia.


24

08 65. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is hypertension.


25

66. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is an eating disorder.

97. (Twice Amended) A compound as claimed in claim 1, which is of formula



wherein




is optionally substituted heteroaryl;

a = 1;

b = 0;

R₁, R₂, R₃, R₄ are hydrogen



A is

R₁₅, R₁₆ are hydrogen;

c = 0;

d = 0;

g = 2, 3, 4 or 5;

B and E are a chemical bond;


Z is R₂₁O₂C-, R₂₁OC-, or R₂₁O-;

R₂₁ is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, or optionally substituted aralkyl;

89
Sub
E4

R' is hydrogen, optionally substituted lower alkyl, halo, optionally substituted alkoxy, optionally substituted aryloxy or optionally substituted aralkyloxy; and R'' is optionally substituted lower alkyl, hydrogen, optionally substituted aralkyloxy, optionally substituted alkoxy, optionally substituted cycloalkylalkyloxy or halo, or a pharmaceutically acceptable salt thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.


102. (Amended) A compound according to claim 1, wherein the compound is





D

Sub
E7




, or

D10

¹²
103: (Amended) A compound according to claim 1, wherein the compound is

T11350



Please add new claim 104 as follows:

--104. A compound according to claim 1, wherein the compound is

Sub
E8

